Summary

Egypt Pharmaceutical Market is expected to grow at a significant rate during the forecast period. One of the main factors influencing the market is the rising demand for pharmaceuticals during the COVID-19 pandemic in order to supply patients with enough medications. Additionally, the government is heavily funding research and development (R&D) projects that enable quick drug discovery for bettering health outcomes. The industry is being positively impacted by this as well as the growing proficiency of leading market participants in specialty pharmaceuticals including innovative biologics and biosimilars, complicated generics, and preventive medicine. Additionally, the increasing use of intelligent automation in the pharmaceutical sector for disease diagnosis and management is fueling market expansion. Furthermore, the creation of a single-window system to speed up the approval of economically viable projects and expedite the drug development process is boosting demand for pharmaceuticals in the nation. Moreover, growing investments in long-term, high-risk projects by different funding outlets are providing industry investors with profitable growth chances.
The Egyptian pharmaceutical market is driven by a number of factors, including the country's large population, increasing healthcare spending, and rising demand for healthcare products and services. The government has also been investing heavily in the healthcare sector in recent years, which has led to an increase in the availability and accessibility of healthcare products and services across the country. The most commonly prescribed therapeutic categories in Egypt are cardiovascular, gastrointestinal, and anti-infective drugs. The country also has a significant demand for generics and over-the-counter (OTC) medications.
Egypt's pharmaceutical industry is dominated by domestic manufacturers, which account for over 70% of the market share. The remaining market share is held by multinational pharmaceutical companies. The top domestic pharmaceutical companies in Egypt include Amoun Pharmaceutical Company, EIPICO, and Memphis Pharmaceutical and Chemical Industries.
In terms of regulations, the Egyptian Ministry of Health and Population is responsible for regulating the pharmaceutical industry in the country. The ministry has implemented a number of reforms in recent years aimed at improving the regulatory environment and promoting investment in the sector.
Overall, the pharmaceutical market in Egypt is expected to continue to grow in the coming years, driven by increasing demand for healthcare products and services, rising healthcare spending, and government investment in the sector.
Adoption of New Regulatory Framework
The new Egyptian administration has released a set of regulations to enhance the pharmaceutical business in Egypt, with the ambitious goal of increasing the industry is driving market expansion during forecast period. The Egyptian Law No. 151 of 2019, declares the establishment of the Egyptian Drug Authority (EDA) as its own entity and the Egyptian Authority for Unified Procurement, Medical Supply, and Technology Management as a separate economic unit. Egyptian Drug Authority (EDA) regulatory framework is governing the pharmaceutical industry in Egypt and has been completely restructured with the goal conceptualizinging, developing, and strengthening the healthcare system and pharmaceutical industry in Egypt, thereby driving the growth of the Egypt Pharmaceutical market. Moreover, the new regulatory framework made it possible for the pharmaceutical industry in Egypt to recover quickly and effectively.
Delayed Governmental Approvals
The pharmaceutical industry in Egypt typically meets technical support miscommunication between governmental and pharmaceutical regulatory affairs, the gap between academia and industry, and regulatory, developmental, and manufacturing challenges beginning with product registration. It also includes delayed governmental approvals and marketing authorization for registered products, the high financial cost of the product registration process, and predatory or below-cost of approved products which in turn hamper the growth of the Egypt pharmaceutical market throughout the forecast period. However, additional regulatory issues based on "win-win" approaches, quick production with real-time regulation, and outcome-based regulation, as well as regulatory activities such as regulatory analytics, regulatory intelligence and knowledge management, correspondence and commitment, authoring, programming, hyperlinking, translations, and data verification, are still to be resolved which limit the growth of the market.
Market Segmentation
Egypt Pharmaceutical Market is segmented on the basis of type, drug classification, mode of purchase, and distribution channel. Based on type, the market is further bifurcated into pharmaceutical drugs and biologics. The pharmaceutical drugs segment is further divided into gynecology drugs, respiratory drugs, dermatology drugs, analgesic drugs, oncology drugs, and others. Based on biologics the sub-segment is divided into Monoclonal Antibodies (MAbS), therapeutic proteins, and vaccines. Based on drug classification, the market is divided into branded drugs and generic drugs. On the basis of mode of purchase, the market is divided into prescription-based drugs and over-the-counter drugs. Based on distribution channel, the market is further divided into hospital pharmacies, retail pharmacies, and online pharmacies.
Market players
MDI Pharma, Merck & Co., Novartis AG, Pharco Pharmaceuticals, Roche Holding AG, Sanofi S.A, EVA Pharma, Orchidia Pharmaceutical Industries, GlaxoSmithKline, Tabuk Pharmaceuticals are the major drivers in the Egypt Pharmaceutical Market.

Report Scope:
In this report, the Egypt Pharmaceutical Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Egypt Pharmaceutical Market, By Type:
o Pharmaceutical Drugs
 Gynecology Drugs
 Respiratory Drugs
 Dermatology Drugs
 Analgesic Drugs
 Oncology Drugs
 Others
o Biologics
 Monoclonal Antibodies (MAbS)
 Therapeutic Proteins, Vaccines
• Egypt Pharmaceutical Market, By Drug Classification
o Branded Drugs
o Generic Drugs
• Egypt Pharmaceutical Market, By Mode of Purchase
o Prescription-Based Drugs
o Over-the-counter Drugs
• Egypt Pharmaceutical Market, By Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Egypt Pharmaceutical Market, By Region
o Cairo
o Alexandria
o Giza Qalyubia
o Port Said Suez
o Rest of Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Egypt Pharmaceutical Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents